个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：
Tan Xu[1,2,3] * ; Wang Jishi[4] * ; Chen Shangjun[5] * ; Liu Li[6] ; Li Yuhua[7] ; Tu Sanfang[7] ; Yi Hai[8] ; Zhou Jian[9] ; Wang Sanbin[10] ; Liu Ligen[11] ; Ge Jian[12] ; Hu Yongxian[13] ; Wang Xiaoqi[1,2,3] ; Wang Lu[1,2,3] ; Chen Guo[1,2,3] ; Yao Han[1,2,3] ; Zhang Cheng[1,2,3] ; Zhang Xi[1,2,3] ;
机构： [1]Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China. [2]Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China. [3]State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China. [4]Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China. [5]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430032, China. [6]Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China. [7]Department of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China. [8]Department of Hematology, The General Hospital of Western Theater Command, PLA, Chengdu, Sichuan 610083, China. [9]Department of Hematology, Henan Cancer Hospital, Zhengzhou, Henan 450008, China. [10]Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan 650032, China. [11]Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China. [12]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China. [13]Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 311100, China.
出处：
DOI： 10.1097/CM9.0000000000003479
ISSN：

关键词： CD19-positive B-cell ALL Relapse/refractory CD19 Fast-CAR-T cells CD19 conventional CAR-T cells Allo-HSCT

摘要：
Treatment with chimeric antigen receptor-T (CAR-T) cells has shown promising effectiveness in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), although the process of preparing for this therapy usually takes a long time. We have recently created CD19 Fast-CAR-T (F-CAR-T) cells, which can be produced within a single day. The objective of this study was to evaluate and contrast the effectiveness and safety of CD19 F-CAR-T cells with those of CD19 conventional CAR-T cells in the management of R/R B-ALL.A multicenter, retrospective analysis of the clinical data of 44 patients with R/R B-ALL was conducted. Overall, 23 patients were administered with innovative CD19 F-CAR-T cells (F-CAR-T group), whereas 21 patients were given CD19 conventional CAR-T cells (C-CAR-T group). We compared the rates of complete remission (CR), minimal residual disease (MRD)-negative CR, leukemia-free survival (LFS), overall survival (OS), and the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between the two groups.Compared with the C-CAR-T group, the F-CAR-T group had significantly higher CR and MRD-negative rates (95.7% and 91.3%, respectively; 71.4% and 66.7%, respectively; P = 0.036 and P = 0.044). No significant differences were observed in the 1-year or 2-year LFS or OS rates between the two groups: the 1-year and 2-year LFS for the F-CAR-T group vs.C-CAR-T group were 47.8% and 43.5% vs. 38.1% and 23.8% (P = 0.384 and P = 0.216), while the 1-year and 2-year OS rates were 65.2% and 56.5% vs. 52.4% and 47.6% (P = 0.395 and P = 0.540). Additionally, among CR patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T-cell therapy, there were no significant differences in the 1-year or 2-year LFS or OS rates: 57.1% and 50.0% vs. 47.8% and 34.8% (P = 0.506 and P = 0.356), 64.3% and 57.1% vs. 65.2% and 56.5% (P = 0.985 and P = 0.883), respectively. The incidence of CRS was greater in the F-CAR-T group (91.3%) than in the C-CAR-T group (66.7%) (P = 0.044). The incidence of ICANS was also greater in the F-CAR-T group (30.4%) than in the C-CAR-T group (9.5%) (P = 0.085), but no treatment-related deaths occurred in the two groups.Compared with C-CAR-T-cell therapy, F-CAR-T-cell therapy has a superior remission rate but also leads to a tolerably increased incidence of CRS/ICANS. Further research is needed to explore the function of allo-HSCT as an intermediary therapy after CAR-T-cell therapy.Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：
the National Natural Science Foundation of China (Nos. 82341201, 82370181), the National Key R&D Program of China (Nos. 2022YFA1103300, 2022YFA1103304), the Chongqing Science and Health Joint Medical Research Project (No. 2024QNXM025), and the Special Project for Talent Construction in Xinqiao Hospital of Army Medical University(No. 2022XKRC001).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：内科
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：内科
第一作者：
第一作者机构： [1]Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China. [2]Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China. [3]State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China.
共同第一作者：
通讯作者：
通讯机构： [1]Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China. [2]Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China. [3]State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China.
推荐引用方式(GB/T 7714)：
Tan Xu,Wang Jishi,Chen Shangjun,et al.Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia[J].Chinese Medical Journal.2025,doi:10.1097/CM9.0000000000003479.
APA：
Tan Xu,Wang Jishi,Chen Shangjun,Liu Li,Li Yuhua...&Zhang Xi.(2025).Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia.Chinese Medical Journal,,
MLA：
Tan Xu,et al."Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia".Chinese Medical Journal .(2025)

相关文献

[1]SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type [2]Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis [3]Glaucomatous Injury of Central Nerve System [4]患高血压冬天护好三部位 [5]前列腺等离子剜切术和钬激光剜除术治疗良性前列腺增生疗效分析 [6]萎缩型老年性黄斑变性患眼地图样萎缩面积的多模态成像定量分析 [7]苯扎托品对大鼠非动脉炎性前部缺血性视神经病变模型神经保护作用初探 [8]甲状腺肿瘤的常见手术方式及icd-9-cm-3编码解析 [9]Observation of fundus and optical coherence tomography angiography manifestations in carotid cavernous fistula patients [10]

资源点击量：28994 今日访问量：0 总访问量：1619 更新日期：2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)